262 related articles for article (PubMed ID: 1886289)
1. Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Inatomi N; Nagaya H; Takami K; Shino A; Satoh H
Jpn J Pharmacol; 1991 Apr; 55(4):437-51. PubMed ID: 1886289
[TBL] [Abstract][Full Text] [Related]
2. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
[TBL] [Abstract][Full Text] [Related]
3. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
Nishida A; Takinami Y; Yuki H; Kobayashi A; Akuzawa S; Kamato T; Ito H; Yamano M; Nagakura Y; Miyata K
J Pharmacol Exp Ther; 1994 Sep; 270(3):1256-61. PubMed ID: 7932178
[TBL] [Abstract][Full Text] [Related]
4. Effects of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl] urea with potent gastric mucosal protective activity on acute gastric lesions and duodenal ulcers in rats.
Sekiguchi H; Hamada K; Taga F; Nishino K
Arzneimittelforschung; 1993 Feb; 43(2):134-8. PubMed ID: 8096133
[TBL] [Abstract][Full Text] [Related]
5. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
Nagaya H; Inatomi N; Satoh H
Jpn J Pharmacol; 1991 Apr; 55(4):425-36. PubMed ID: 1886288
[TBL] [Abstract][Full Text] [Related]
6. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Barradell LB; Faulds D; McTavish D
Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
[TBL] [Abstract][Full Text] [Related]
7. [Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].
Inatomi N; Murakami I; Asano S; Inada I; Satoh H
Nihon Yakurigaku Zasshi; 1996 Dec; 108(6):333-43. PubMed ID: 9017687
[TBL] [Abstract][Full Text] [Related]
8. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
[TBL] [Abstract][Full Text] [Related]
9. Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study.
Umeda N; Miki K; Hoshino E
J Clin Gastroenterol; 1995; 20 Suppl 1():S17-23. PubMed ID: 7673609
[TBL] [Abstract][Full Text] [Related]
10. Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine.
Sakaguchi M; Ashida K; Umegaki E; Miyoshi H; Katsu K
J Clin Gastroenterol; 1995; 20 Suppl 2():S27-31. PubMed ID: 7594334
[TBL] [Abstract][Full Text] [Related]
11. Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity.
Satoh H
Curr Pharm Des; 2013; 19(1):67-75. PubMed ID: 22950496
[TBL] [Abstract][Full Text] [Related]
12. Effect of lansoprazole on peptic ulcers.
Ohashi T; Sakata J; Haraguchi Y; Eto T
J Clin Gastroenterol; 1995; 20 Suppl 2():S83-5. PubMed ID: 7594350
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of 2-[[(4-fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1H- benzimidazoles as antiulcer agents.
Kubo K; Oda K; Kaneko T; Satoh H; Nohara A
Chem Pharm Bull (Tokyo); 1990 Oct; 38(10):2853-8. PubMed ID: 2076571
[TBL] [Abstract][Full Text] [Related]
14. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
Spencer CM; Faulds D
Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
[TBL] [Abstract][Full Text] [Related]
15. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Ogawa N
Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals.
Yamaguchi T; Aihara K; Yamada S; Narita S; Kogi K
Jpn J Pharmacol; 1993 Aug; 62(4):363-71. PubMed ID: 8230863
[TBL] [Abstract][Full Text] [Related]
17. Effect of a novel xanthine derivative on experimental ulcers in rats.
Tanaka T; Morioka Y; Gebert U
Arzneimittelforschung; 1993 May; 43(5):558-62. PubMed ID: 8329000
[TBL] [Abstract][Full Text] [Related]
18. [Effects of lansoprazole on indomethacin-induced gastric bleeding and mucosal lesions in rats].
Murakami I; Asano S; Yukishige K; Nagaya H; Satoh H; Inatomi N
Nihon Yakurigaku Zasshi; 1996 Dec; 108(6):323-32. PubMed ID: 9017686
[TBL] [Abstract][Full Text] [Related]
19. Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat.
Kuwayama H; Matsuo Y; Eastwood GL
Am J Med; 1991 Aug; 91(2A):15S-19S. PubMed ID: 1882902
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting quality of ulcer healing after lansoprazole treatment.
Ito G; Nakagawara M; Watanabe F; Ooi S; Nawano M; Hanai H; Kaneko E
J Clin Gastroenterol; 1995; 20 Suppl 2():S62-6. PubMed ID: 7594344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
